WELL

From a fundamental perspective, Welltower's performance metrics reveal impressive growth. The company reported a staggering year-over-year revenue growth of 3582.4%, with a quarterly growth rate of 38.3%. This is complemented by an exceptional EPS growth of 157.9% and an EPS of $2.07. The gross margin is extraordinarily high at 3917.7%, and the operating margin is also robust at 333.0%. However, the high P/E ratio of 99.8 and forward P/E of 70.4 suggest that the stock may be overvalued relative to its growth, although analysts remain bullish with a consensus rating of BUY, including four strong buy recommendations. The average analyst target price of $235.48 indicates a potential upside of about 11.2% from the current price.

Welltower has not scheduled its next earnings release within the next 30 days, with the last quarter reported on March 31, 2026. Recent news indicates mixed institutional activity, with SG Americas Securities LLC boosting its position, while BI Asset Management Fondsmaeglerselskab A S reduced its stake. Investors should monitor any developments regarding margin expansion or compression, as the extremely high gross and operating margins may not be sustainable. A key metric to watch will be the upcoming revenue growth trajectory, particularly in the context of ongoing economic conditions and potential shifts in the healthcare sector.